A new oral option for weight and blood sugar support: what the latest trial suggests

Why oral weight-support options are gaining attention

In recent years, medications that act on the GLP-1 pathway have become a cornerstone of care for type 2 diabetes and weight management. For many people, however, the idea of injections—or the need for careful storage—can be a barrier. That’s why researchers are increasingly exploring tablet-based approaches that may offer similar metabolic support in a more convenient format.

What is orforglipron, and how is it different?

Orforglipron is an investigational daily oral medication studied in a large phase 3 trial involving adults with type 2 diabetes. It’s designed to work on GLP-1 receptors, supporting pathways that influence appetite, digestion, and insulin-related processes. The key distinction is its drug “type”: orforglipron is considered a small-molecule compound, while oral semaglutide is a peptide medication.

• Small-molecule drugs like orforglipron are generally engineered to be absorbed through the gut and may be easier to manufacture.
• Oral semaglutide is a peptide, with a structure more closely related to the natural GLP-1 hormone.
• Because both are taken orally in these studied formats, they also avoid the refrigeration requirements typical for injectable GLP-1 medicines.

Key results from a 52-week phase 3 trial

A 52-week phase 3 study enrolled 1,698 adults with type 2 diabetes across six countries. The goal was to compare a daily orforglipron tablet against existing oral semaglutide products. Researchers focused on HbA1c, a standard marker of average blood glucose over roughly three months, and also tracked weight changes.

HbA1c (blood sugar control)

Starting from an average HbA1c of about 8.3%, after 52 weeks orforglipron reduced HbA1c by approximately 1.71–1.91 percentage points. Oral semaglutide reduced it by about 1.47 percentage points. In other words, the trial suggested stronger glucose control with orforglipron under the study conditions.

Weight change

Participants taking orforglipron lost more weight on average than those taking oral semaglutide. Reported weight loss was roughly 6.1–8.2 kg with orforglipron compared with about 5.3 kg with oral semaglutide. (Individual results varied, as is typical in clinical trials.)

Side effects and tolerability matter

As with many GLP-1–related therapies, gastrointestinal symptoms are a major consideration. In this trial, nausea, vomiting, diarrhea, or constipation were reported more frequently among people taking orforglipron than among those taking oral semaglutide.

• GI side effects were reported in about 59% of orforglipron participants versus roughly 37–45% with oral semaglutide.
• Discontinuation due to adverse effects occurred in around 10% of people taking orforglipron, compared with about 4–5% on semaglutide.
• One proposed explanation is that orforglipron may create a more noticeable daily concentration peak, which can influence how strongly side effects appear.

When evaluating “which option is better,” effectiveness and tolerability often go hand in hand—because long-term use depends not only on results, but also on how manageable side effects are.

What this could mean for women’s health and real-life adherence

Weight changes and blood sugar control are only part of the story. For many women, day-to-day factors—comfort, convenience, and the ability to stick with a regimen—can strongly affect whether treatment (or a therapy plan) is sustainable. Oral options may reduce the injection-related barrier and, in some contexts, simplify logistics compared with injectable therapies.

At the same time, higher rates of GI symptoms and discontinuation risk can influence adherence. If you’re comparing options—or discussing next steps with a clinician—worth asking about: how side effects are handled, whether dose adjustments are possible, and what monitoring is recommended.

What’s next: trials beyond diabetes

Orforglipron is also being studied in people with obesity without diabetes, which could clarify where it fits best. Until results are available, it’s best to view these findings as promising but still evolving evidence.

Bottom line: In a 52-week phase 3 trial in type 2 diabetes, orforglipron outperformed existing oral semaglutide options for HbA1c reduction and weight loss, but was associated with more gastrointestinal side effects and a higher discontinuation rate. For anyone considering GLP-1–related therapies, the “best” option is likely the one that balances effectiveness with tolerability—based on individual health status and clinician guidance.

Disclaimer: This article is for informational purposes only and does not replace medical advice. Before starting any supplement or medication, including GLP-1–related therapies, consult a qualified healthcare professional—especially if you have diabetes, gastrointestinal conditions, are pregnant, or take other medicines.